Currently, NP-based antiviral drug development has formed two major classes of inhibitors that target on NP interaction with virus RNA96 and block formation of vRNPs by the mechanism of NP oligomerization
Currently, NP-based antiviral drug development has formed twomajor classes of inhibitors that target on NP interaction with virusRNA96 and block formation of vRNPs by the mechanism of NPoligomerization